Intuitive Surgical Slips on Legal Charge, Pricing Plans

Key Moments

Earnings Beat Overshadowed by Legal Charge

Investing.com — Intuitive Surgical stock fell 7.6% in pre-open trading to reach $404.8 after the company’s Q3 2026 results, released after Tuesday’s closing bell, revealed a $450 million pre-tax charge tied to the settlement of the “In re: da Vinci Surgical Robot Antitrust Litigation” class action. The one-time charge pushed GAAP net income down to $523 million, or $1.49 per diluted share, compared with $704 million, or $1.95 per diluted share, in the same quarter a year earlier.

On an adjusted basis, the company delivered earnings per share of $3.00, above the consensus estimate of $2.65. Revenue came in at $3.05 billion, also ahead of the $2.91 billion forecast. Nonetheless, markets looked past the headline beats and centered on the implications of the legal settlement and future pricing strategy.

Pricing Strategy Signals Pressure on High-Margin Revenue

During the earnings call, management detailed forthcoming pricing initiatives affecting the da Vinci ecosystem. The company stated that pricing actions – including an extended-use instrument program in the U.S. and a China-specific price reduction starting in November – are expected to reduce da Vinci instrument and accessory revenue per procedure by approximately 3%-5% on a mix-constant basis once fully implemented in 2027.

Because instruments and accessories make up the core of Intuitive Surgical’s high-margin recurring revenue base, investors interpreted the update as a structural challenge to near-term profitability rather than a catalyst for immediate growth. The explicit quantification of the expected revenue-per-procedure decline intensified concerns about the earnings trajectory over the coming years.

Procedure Growth Mix Raises Additional Concerns

Investor sentiment was further pressured by a slowdown in U.S. procedure growth. Domestic da Vinci procedure volume increased 10%, which was described as the weakest U.S. growth rate since the COVID period. In contrast, international procedures increased 20%, and total procedures grew 15%, highlighting a divergence between domestic and overseas momentum.

JPMorgan maintained its Overweight rating on the stock and raised its price target to $475 after the results, offering some measure of support. However, the revised target did not prevent substantial pre-market selling pressure.

Stock Move Driven by Company-Specific Factors

The broader equity environment did little to offset the decline in Intuitive Surgical shares. The S&P 500 edged up 0.1% and the NASDAQ gained 0.4%, indicating that the stock’s move reflected company-specific developments rather than a broader market or sector trend.

The report noted that there were no major central bank decisions or significant economic data releases exerting a material impact on the medical technology space on the day. As a result, trading in Intuitive Surgical was largely driven by the earnings release, litigation charge, and pricing outlook.

Market Weighs Legal, Pricing, and Growth Headwinds

In combination, the sizable one-off legal expense, the deliberate and quantified reduction in the company’s most profitable revenue stream, and a clear slowdown in U.S. procedure growth proved difficult for investors to overlook. This was the case even as the company pointed to record system placements and a strong revenue beat.

The confluence of these factors left Intuitive Surgical shares under notable pressure heading into the regular trading session, as market participants reassessed the balance between the company’s current operational strength and its evolving profitability profile.